Roivant Sciences (ROIV) reported continued pipeline momentum at the Bank of America Global Healthcare Conference on September 22, 2026, presenting new clinical data for its Immunovant portfolio and early commercial details for its TYK2 inhibitor brepocitinib.
Shares of Roivant fell 2.49% in premarket trading to $38.019, down from a previous close of $38.99. The stock has traded between $14.50 and $42.50 over the past 52 weeks. Late-day prints showed the share around $39.77, down 0.53%.
Brepocitinib, marketed as LISRAYA, launched roughly three weeks ago for dermatomyositis. CEO Matt Gline described the rollout as deliberately paced. "Our both internal and externally disclosed path there is slow and steady. That's what we said over and over and over again. The truth is, we are 3 weeks in, so there's really very little to say that's productive," Gline said.
Roivant also provided additional head-to-head context for brepocitinib in non-infectious uveitis. An estimated 50,000 patients currently use TNF inhibitors for the condition. In comparative data, time to treatment failure averaged more than 12 months on high-dose brepocitinib, versus 5.6 months on HUMIRA and roughly three months on placebo.
Data from Immunovant's IMVT-1402 program in difficult-to-treat rheumatoid arthritis drew particular attention. Approximately 60% of enrolled patients had previously failed a JAK inhibitor. During the open-label period, about 70% of patients achieved ACR20, 50% reached ACR50, and 35% hit ACR70. In a second-period cohort, roughly 67% achieved ACR50 or better and about 50% achieved ACR70.
Immunovant's Graves' disease program also reported encouraging Phase II results from a single-site study in Germany. Of 21 patients treated, 17 — or 81% — maintained disease control six months after stopping therapy. Roughly 60% were able to stop or meaningfully reduce anti-thyroid drugs while achieving normalized thyroid hormone levels. Roivant noted that approximately 350,000 U.S. patients with uncontrolled Graves' disease have exhausted treatment options, and about 20,000 thyroidectomies are performed annually.
"In our phase II study, I think close to 60% of patients were able to get off ATDs, or to reduce their ATD dose meaningfully while getting normalized from a thyroid hormone perspective. I think anything like our phase II data would be a grand slam lights out outcome for us," Gline said.
Gline defended the breadth of Roivant's portfolio against broader biotech peers. "I would not trade our pipeline for basically any other pipeline in biotech. I think if you drew a chart of valuation on one axis and probability of exceeding $20 billion of sales on another axis, that we are at a pretty unique corner there," he said.
On milestones ahead, Roivant indicated that cutaneous lupus erythematosus headline data from brepocitinib trials is expected by the end of 2024, with rheumatoid arthritis and Graves' disease updates from Immunovant slated for later in 2026 and into 2027. Registration data for myasthenia gravis and Graves' disease are expected in 2027.
Roivant's asset-sale strategy — including the 2019 divestiture of a portfolio to Sumitomo Pharma and the sale of its anti-TL1A antibody program to Roche across 2023 and 2024 — continues to fund the company's diversified pipeline approach, Gline said.
"I think we're pretty good at choosing indications, pretty good at running studies, and I think that combination is really potent for what we think we can deliver," he added.
